<DOC>
	<DOCNO>NCT00759577</DOCNO>
	<brief_summary>This open-label single center trial study improvement symptom bother quality life overactive bladder patient self titrate solifenacin 5mg 10 mg . The study design reflect real world condition typical male female OAB patient present treatment .</brief_summary>
	<brief_title>Feasibility `` At-home '' Titration Solifenacin</brief_title>
	<detailed_description>Open-label single center trial study improvement symptom bother quality life OAB patient self titrate solifenacin 5mg 10 mg . The study design reflect real world condition typical male female OAB patient present treatment . After eligibility confirm , subject complete number questionnaire include patient perception bladder condition ( PPBC ) 12 , Overactive Bladder Questionaire ( OAB-q13 ) , visual analog scale ( VAS ) 0-100 assess bother urge incontinence , urgency , frequency nocturia past week .</detailed_description>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<criteria>1 . Ambulatory male female patient age ≥18 year age able use toilet without difficulty . 2 . Symptoms OAB &gt; 3 month . 3 . Written informed consent ( IC ) obtain . 4 . Capable filling questionnaire . 5 . Patients may include never expose anticholinergic agent specify treatment OAB . Patients may also include previously treat FDAapproved anticholinergic agent treatment OAB oxybutynin chloride ( generic oxybutynin chloride , Ditropan XL® , Ditropan® , OxytrolTM ) , tolterodine tartrate ( Detrol® Detrol LA® ) , trospium chloride ( Sanctura® , Sanctura XR® ) longer receive treatment least 14 day . 6 . Patients undergo nonmedical treatment OAB ( pelvic floor exercise behavioral modification ) must treatment initiate least 4 week prior enrollment change regimen . 7 . Normal urine analysis sterile urine specimen ( culture negative ) 1 . Previous treatment darifenacin 2 . Duration urgency without urge incontinence , usually accompany frequency nocturia &lt; 3 month 3 . Significant stress incontinence mixed stress/urge incontinence stress predominant factor determine Investigator 4 . Evidence urinary tract infection ( UTI ) ; chronic inflammation interstitial cystitis bladder stone 5 . Clinically significant outflow obstruction ( benign prostatic hyperplasia [ BPH ] ) determine Investigator . 6 . Uncontrolled narrow angle glaucoma , urinary gastric retention 7 . All patient severe renal hepatic impairment exclude trial ; dose increase 10mg permit patient moderate hepatic impairment evidence liver function test . 8 . Women childbearing potential pregnant intend become pregnant study sexually active practice unreliable method birth control , judge Investigator , lactate study . 9 . A history bladder cancer 10 . Known suspected hypersensitivity solifenacin succinate , component ( lactose monohydrate , corn starch , hypromellose 2910 , magnesium stearate , talc , polyethylene glycol 8000 titanium dioxide yellow ferric oxide [ 5mg tablet ] red ferric oxide [ 10 mg tablet ] ) , anticholinergic . 11 . Participation clinical trial ( except patient registry trial ) involve investigational drug , within 30 day prior enrollment 12 . Patients chronic severe constipation history diagnose gastrointestinal disease obstruction . 13 . Patients hematuria . 14 . Any clinical condition , , opinion Investigator , would allow safe completion study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>